Loading...

Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside

The Bruton tyrosine kinase (BTK) inhibitor, ibrutinib, has been approved for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstroms macroglobulinemia. Acquired resistance to ibrutinib due to BTK C481S mutation has been reported. Mutations in PLC?2 can also mediate resi...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget
Main Authors: Wu, Jingjing, Zhang, Mingzhi, Liu, Delong
Format: Artigo
Language:Inglês
Published: Impact Journals LLC 2016
Subjects:
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5351700/
https://ncbi.nlm.nih.gov/pubmed/27776353
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12786
Tags: Add Tag
No Tags, Be the first to tag this record!